Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

GPR1 antagonistic polypeptide and derivative and application thereof

A derivative, antagonistic technology used in biotechnology and biomedicine

Active Publication Date: 2019-06-28
SHENZHEN INST OF ADVANCED TECH
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As GPR1 is one of the members of GPCRs, there is still no drug that directly targets GPR1 to treat clinical cancer.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • GPR1 antagonistic polypeptide and derivative and application thereof
  • GPR1 antagonistic polypeptide and derivative and application thereof
  • GPR1 antagonistic polypeptide and derivative and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0108] Example 1: Panning, amplification, purification, sequencing and synthesis of GPR1 antagonistic polypeptide LRH12-G2.

[0109] This example is mainly for the purpose of screening positive phages that specifically bind to GPR1, and then by amplifying and purifying the positive phages, extracting phage single-stranded DNA (ssDNA) for sequencing, analyzing and comparing the obtained sequences, and finally synthesizing high-purity phages. The antagonistic polypeptide LRH12-G2.

[0110] details as follows:

[0111] 1. Establishment of 293T cell line with permanent high expression of GPR1: 293T-GPR1 + / + / LRH

[0112] ①Select vigorously growing luminescent human 293T cells, and the day before transfection, use 5×10 5 cells / well, inoculated in a 6-well plate, cultured until the second day, the cell fusion degree was 60%;

[0113] ② Transfect on the second day, take one culture well of a 6-well plate as a unit, dilute 3 μg of plasmid with 200 μL of opti-MEM medium, and dilute...

Embodiment 2

[0131] Example 2 The GPR1 antagonistic polypeptide LRH12-G2 can effectively alleviate the inhibitory effect of chemerin on the cAMP signaling pathway.

[0132] (1) Cyclic adenosine monophosphate (cAMP) ELISA:

[0133] ① Cell plating: Wild-type 293T cells and 293T cells with high expression of GPR1 (293T GPR1 + / + ), with 5ⅹ10 5 Each well was inoculated in a 6-well cell culture plate, and the medium volume of each well was 1 mL. After being placed in an incubator for 24 hours, starved overnight, and LRH12-G2 polypeptides with different concentration gradients (3 μM, 0.3 μM, 0.03 μM) were added. , Fosklin (25μM) and chemerin (30nM) for 6h;

[0134] ②Sample preparation: Add 300 μL of cell lysate to each well, place at 4°C for 20 minutes, scrape and collect cells with a cell scraper, mix them upside down, centrifuge at 12,000 rpm for 10 minutes, and collect the supernatant;

[0135] ③ Determination of sample concentration: the sample concentration is determined by BCA method;

...

Embodiment 3

[0143] Example 3 GPR1 antagonistic polypeptide LRH12-G2 can effectively inhibit calcium (Ca 2+ ) inflow effect.

[0144] ① Cell plating: Wild-type 293T cells and 293T cells with high expression of GPR1 (293T GPR1 + / + ), with 5ⅹ10 3 Each cell / well was inoculated in a 96-well cell culture plate, the volume of medium in each well was 200 μL, placed in an incubator for 24 hours, and then starved overnight;

[0145] ②Reagent configuration: dissolve probenecid into 1mL buffer solution to prepare probenecid with a concentration of 250nM, shake well, add to fluorescent reagent for use;

[0146] ③Remove the cell culture medium, add LRH12-G2 polypeptide and chemerin (0.3nM) with different concentration gradients (30μM, 3μM, 0.3μM, 0.03μM, 0.003μM) for 30 minutes, and then add 100μL of the above fluorescent reagent to each well;

[0147] ④ Place at 37°C for 30 minutes, then at room temperature for 30 minutes;

[0148] ⑤Measure the fluorescence absorbance at excitation light 494nm and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a GPR1 antagonistic polypeptide and a derivative and application thereof and particularly relates to a GPR1 antagonistic polypeptide shown in SEQ ID No.1-7 and a derivative thereof. The derivative of the binding peptide is a product obtained in the mode that conventional modification is conducted on a GPR1 binding peptide amino acid side chain group and an amino terminal ora carboxyl terminal of a GPR1 antagonistic polypeptide fragment or a product obtained in the mode that a label for detection or purification of polypeptide or protein is linked to the GPR1 antagonistic polypeptide. The binding peptide and the derivative thereof can be combined with GPR1 in vitro, by stopping combination of chemerin and GPR1, increase of the cAMP concentration is promoted, the (Ca2+) influx caused by chemerin is inhibited, effective micromolecule treatment drugs are provided for diseases, such as breast cancer, of high-expression GPR1 receptors, and the GPR1 antagonistic polypeptide can be widely applied in the fields of medicine and biology.

Description

technical field [0001] The present invention relates to the field of biotechnology and biomedicine, specifically, the present invention is the female reproductive disease target GPR1 receptor antagonizing polypeptide LRH12-G2 and its derivatives and applications. Background technique [0002] Breast cancer is the second deadliest cancer in the world after lung cancer, and it continues to destroy the life and health of millions of women and their families around the world. According to the latest statistics from the International Cancer Research Center of the World Health Organization, there were 1.67 million new cases of female breast cancer worldwide in 2012, accounting for 22.9% of all female malignant tumors; 460,000 women died of breast cancer, accounting for 13.7% of all female malignant tumor deaths %, accounting for 1.7% of all female deaths, approximately 1 in 4 cancer-related women develop breast cancer. The age-standardized incidence rate of female breast cancer i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/08C07K7/06C12N15/11A61K38/10A61K38/08A61P1/16A61P3/10A61P29/00A61P35/00A61P15/08
Inventor 张键代小勇张居作王鹤霏朱雯李荣荣
Owner SHENZHEN INST OF ADVANCED TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com